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Abstract 
Variant factor X in an individual with a mild bleeding tendency was suspected based on deficient procoagulant activity (10-20% of 
normal) and antigen (30-35% of normal) levels of plasma factor X. Heteroduplex analysis of factor X gene exons indicated 
heterozygosity for mutations in both exons 6 and 4, confirmed by direct sequencing of the amplified exons. Substitution of C by T at 
nucleotide position 13 984 (Arg-139 to Cys) was found in the factor X gene exon 6 of the propositus. This mutation creates a BsmI site 
and the patient ested heterozygous for the BsmI cleavage involved, as did one of his two daughters. In addition, exon 4 was found to 
have the normal A and a novel C (Asn-57 to Thr) at nucleotide position 9338. The exon 4 mutation creates a BsaJI site, detectable after 
amplification mismatch to remove an existing BsaJI site. Both the patient and the second of his two daughters were heterozygous for this 
cleavage. The two variant proteins are called factors Xwe,atche e I (Arg-139 to Cys) and II (Asn-57 to Thr). A mixed variant isolate 
derived from the plasma of the propositus exhibited heavy/light chains of normal size, as well as an apparent single-chain molecule not 
dissociable by reducing agent. A single-chain molecule would be predicted for form I, if the mutation blocks processing cleavages that 
normally remove a tripeptide interposed between the heavy and light chains. A Western blot of partially purified factor X from the 
daughter who inherited the form I defect revealed a component migrating the same as the putative single-chain species. Based upon the 
factor X activity vs. antigen ratios for the propositus and both daughters, both forms I and II are probably dystunctional molecules. 
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1. Introduction 
Coagulation factor X circulates as disulfide-linked light 
and heavy chains created by removal of a tripeptide, 
Arg- 140-Lys- 14 l-Arg- 142, during processing [ 1 ]. The light 
chain composes the amino-terminal portion of the molecule 
that is involved in membrane and Ca2+-binding interac- 
tions, thought o be mediated primarily by y-carboxylated 
glutamic acid (Gla) residues. The heavy chain contains an 
activation cleavage site [2] and the serine protease catalytic 
domain [1]. Factor X can be activated to factor Xa physio- 
logically by the extrinsic (factor VIIa/t issue factor com- 
plex) and intrinsic (factor IXa/factor Villa complex) path- 
ways in the presence of Ca 2+ and phospholipid, and 
nonphysiologically b  an enzyme in Russell's viper venom 
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(RVV-X), that requires only Ca 2+ its cofactor. Activators 
of factor X cleave the Arg-194-Ile-195 bond in the amino- 
terminal part of the heavy chain, with creation of a 52-re- 
sidue activation peptide [2]. Factc,r Xa combines with 
factor Va on cell membrane surfaces in the presence of 
Ca 2+ to form prothrombinase [3]. II is evident that multi- 
ple specific molecular interactions occur between factors 
X/Xa  and other coagulation factors. 
The factor X gene has been localized to chromosome 
13 [4,5] and contains eight exons and seven introns [5-7]. 
In the present study, low circulating levels of factor X 
antigen and even lower plasma activity levels attributable 
to factor X in an individual with a mild bleeding tendency 
suggested the occurrence of a genetically determined ys- 
functional molecule. Thus, the factor X gene exons 1 
through 8 of the propositus were amplified using the 
polymerase chain reaction, PCR [811, and subsequent het- 
eroduplex analyses [9] and direct DNA sequencing [10] 
were carried out. The simultaneous occurrence of two 
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variant forms of factor X was substantiated bythe fact that 
the mutations egregated separately to respective daugh- 
ters. 
2. Materials and methods 
2.1. Propositus 
The case is a 49-year old man with a life-long, mild 
bleeding tendency; family history was otherwise negative. 
Factor X procoagulant levels as measured using the RVV- 
X assay, intrinsic (activated partial thromboplastin time, 
APTT) and extrinsic (prothrombin time, PT) blood coagu- 
lation assays were all abnormally low when compared with 
the plasma factor X antigen level of about one-third of 
normal (Table 1), measured by a specific radioimmunoas- 
say [11 ]. Plasma samples from each of his two daughters, 
both of whom were asymptomatic, exhibited approxi- 
mately half the expected factor X clotting activity levels in 
the presence of high/above normal antigen levels (Table 
1). 
2.2. General methods 
Factor X activation by extrinsic and intrinsic pathways 
was determined from one-stage coagulation assays in the 
BBL FibroSystem (Baltimore, MD, USA) for the PT and 
for APTT, respectively. The latter assays and activation of 
factor X with Russell's viper venom (RVV-X) were all 
carried out according to procedures previously described 
[12]. Genomic DNA [13] and citrate-anticoagulated plasma 
were prepared from peripheral blood samples collected 
using approved institutional protocols. Oligonucleotide 
primers and procedures described in a previous tudy from 
this laboratory were used to amplify by the polymerase 
chain reaction, PCR, all eight exons of the normal and 
Wenatchee factor X genes [14]. To screen for heterozy- 
gous occurrences of mutations, non-denaturing elec- 
trophoresis [9] in the MDE Gel system (AT Biochem, 
Malvern, PA, USA) was utilized. Gene exons amplified by 
the PCR as previously reported [14] were utilized as the 
test materials. The PCR-amplified products of factor X 
gene exons 1 through 8 were prepared for sequencing in 
pCR" using the TA Cloning system (Invitrogen, San Diego, 
CA). Sequence analyses, both using pCR" and direct use 
of the PCR products before cloning, were carried out with 
Sequenase 2 kits (US Biochemicals, Cleveland, OH) and 
[35S]crdATP, 1300 Ci/mmol (DuPont/NEN, Wilmington, 
DE, USA). The PhastGel system (Pharmacia LKB Bio- 
technology) of sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis, SDS-PAGE, was used to carry out separa- 
tions of reduced and non-reduced samples on Gradient 
10-15 gels supplied by the manufacturer. The molecular 
weight standard employed in this procedure, Rainbow 
Markers (14300 to 200000 kDa range), was purchased 
from Amersham, Arlington Heights, IL, USA. The protein 
bands were visualized using the PhastGel Silver Kit 
(Pharmacia LKB Biotechnology). 
2.3. Verification of mutations using restriction enzymes 
It was found using computer assisted analyses (Univer- 
sity of Wisconsin Genetic Computer Group) that the factor 
Swenatche e I mutation creates a BsmI recognition site GA 
{FUNC {(A{UNDERLINE {T}}GCN/N)}} and that the 
factor Xwenatche e II mutation creates a BsaJI recognition 
site (C/CNNGG). Thus, for form I, exon 6 of the factor X 
gene was amplified in the usual manner by the PCR and 
compared with the amplified normal exon 6 by 4% agarose 
gel electrophoresis after reaction with BsmI (US Bio- 
chemicals). To confirm the occurrence of form II, an 
antisense PCR primer, CGAGGCCGTCTTTACATTTGg 
(single base change in lower case), was designed to abolish 
a normal BsaJI cleavage site that is one base 3' to the 
variant mutation site. Together with an exon 4 sense 
primer, tttgtcgacTGATGCCGGAAACAGCTTGCAG (14), 
it was used to produce a truncated exon 4 fragment of 120 
bp by the PCR. Using BsaJI digestion (New England 
BioLabs, Beverly, MA, USA) and gel electrophoresis in 
Table 1 
Coagulation results 
Test * Patient Daughter A Daughter B Normal Range 
Prothrombin time (PT; s) 33.8 16.1 15.4 14.5-16.0 
Partial thromboplastin time (APTT; s) 77.0 46.0 43.0 35.0-42.0 
Factor X assay (% of normal) 
Procoagulant activity 
RVV-X 1.3 27 24 70-130 
Intrinsic 5.4 50 40 70- 130 
Extrinsic 3.4 57 72 70-130 
Antigen level 30 150 120 70-130 
DNA analysis (genotype) Cys- 139 Cys- 139 Arg- 139 Arg- 139 
Thr-57 Asn-57 Thr-57 Asn-57 
" PT and extrinsic activation are with Inovin (Dade/Baxter) as thromboplastin; APTT and intrinsic activation with kaolin activation, as performed on a 
CoaScreener. For all three subjects' plasmas, PT and APTT corrected to mid-normal range on 1 : l mix with normal plasma pool. 
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4% agarose, the presence of the form II mutation is 
indicated by fragments of 96 and 24 bp. 
2.4. Production, purification and use of  a Ca2 +-dependent 
monoclonal antibody against human factor X 
Highly purified human factor X was used for mono- 
clonal antibody development by established procedures 
[15]. Culture supernatants were screened with a solid-phase 
radioimmunosorbent assay [12] in microtiter plates coated 
with factor X in the presence of 5 mM CaC1 z or 5 mM 
Na2EDTA. A single clone reacted with the antigen in the 
presence of CaCl 2, but not in the presence of NazEDTA. 
This single CaZ+-dependent antibody hybridoma was used 
to produce ascites fluid in Balb-c mice [15]. The ascites 
fluid was used to derive purified monoclonal antibody 
using the caprylic acid method [16]. From 36 ml of ascites 
fluid approx. 68 mg of purified IgG was obtained. Upon 
testing by electrophoresis on Agarose Universal Film in 
the Model No. 470100 Flp System (Ciba-Corning, Palo 
Alto, CA, USA) the purified material was shown to be 
essentially homogeneous. An immunosorbent was prepared 
by reacting 54 mg of the purified antibody with 5 ml 
settled bed volume of Affi-Gel l0 (Bio-Rad Laboratories), 
and a column with bed dimensions of 1 × 6 cm and with 9 
mg antibody/ml bed volume was produced. 
2.5. Purification of normal and Wenatchee I and H factors 
X 
Normal factor X was purified both from pooled plasma 
from normal volunteers [11] and by the following proce- 
dure developed for the efficient isolation of variant pro- 
teins. To obtain factors Xweoat~he e I and II (combined), 
platelet-poor plasma (30 ml) of the propositus in this study 
was buffered at pH 7.5 by addition of Tris-HC1, adjusted 
to this pH, to a concentration of 20 mM and Na 2 EDTA to 
a concentration of l0 raM. The plasma was applied to a 
Pharmacia DEAE-Sepharose Fast Flow column (1.6 × 2.5 
cm) in 20 mM Tris-HC1, 10 mM Na2EDTA, pH 7.5, and 
the column was washed extensively with the same buffer. 
Bound proteins were eluted with a linear gradient of NaCI 
from 0 to 0.8 M in 20 mM Tris-HC1, 5 mM CaCI 2, pH 
7.5. Active fractions screened by the RVV-X assay were 
dialyzed against 8 mM Tris-HCl, 60 mM NaC1, 2 mM 
CaCle, pH 7.5 and loaded onto a heparin-agarose (Phar- 
macia LKB Biotechnology, Piscataway, NJ, USA) column 
(1 × 6 cm). Bound proteins were eluted with a linear 
gradient of NaC1 from 0 to 1 M NaC1 in 8 mM Tris-HC1, 2 
mM CaCI 2, pH 7.5. Active fractions screened by the 
RVV-X assay were dialyzed against 8 mM Tris-HCl, 60 
mM NaC1, 2 mM CaC12, pH 7.5, and loaded onto an 
anti-factor X CaZ+-dependent monoclonal antibody im- 
munosorbent column (see above). Bound proteins were 
eluted in the same buffer by applying a linear gradient of 0 
to 8 mM Na2EDTA. The active fractions screened by the 
RVV-X assay were concentrated in a dialysis bag with 
polyethylene glycol (PEG 6000) arad dialyzed against 20 
mM Tris-HC1, 150 mM NaCI, pH 7,45, and stored at 
- 70 ° C. The concentration of purified factors Xwcnat~he e I 
and II (combined) was determined by a radioimmunoassay 
specific for factor X [l l] and the values obtained were 
found to be in agreement with those obtained using an 
extinction coefficient of 11.6 [17]. A total of 26 /~g of 
purified material was obtained. Based upon the original 
plasma concentration of 2.7 /~g/ml determined by the 
radioimmunoassay, the recovery wa,,~ approx. 32%. 
2.6. Western blotting 
Samples were subjected to SDS-PAGE with/without 
reducing agent using the Pharmacia PhastGel system. Pro- 
tein bands for factor X from the subjects tudied, partially 
purified from 1 ml or less of plasma by BaC12 adsorption 
and ammonium sulfate precipitation [11], were transferred 
to a nitrocellulose membrane using the Model TE22 sys- 
tem (Hoefer Scientific Instruments, San Francisco, CA). 
Primary polyclonal antibody (1:300) produced in the rabbit 
(#8542) against human factor X previously by Dr. Daryl 
Fair [11] and alkaline phosphatase-labeled goat anti-rabbit 
IgG (Sigma) as secondary antibody at a 1:1000 dilution 
were used for Western blotting [18], employing BCIP/NBT 
(Calbiochem, La Jolla, CA) as the indicator substrate. 
3. Results 
3.1. Heteroduplex analyses 
To investigate the occurrence of factor X gene muta- 
tions in the propositus, heteroduplex analyses were carried 
out. In this procedure, heterozygous occurrences of muta- 
tions are evidenced by the presence of a double band 
A B C D 
Fig. t. Heteroduplex analysis of factor X gene exons 6 and 4 of the 
propositus. Lanes A and C represent variant exons 6 and 4 and lanes B 
and D represent the corresponding ormal exons. Components with lower 
mobility in the variant exon samples indicate the presence ofheterodu- 
plexes and the occurrence of heterozygous mutations. 
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Fig. 2. Sequencing autoradiographs substantiating the occurrence of two different heterozygous factor X gene mutations in the propositus. The 
PCR-amplified exons were analyzed without cloning into the sequencing vector. Both C and T occur at position 13 894 in the Wenatchee I gene, while A 
and C occur at position 9338 in the Wenatchee II gene, confirming heterozygous occurrence of a mutation in both cases. 
(instead of a single band) in PCR-amplified fragments. 
Mixtures of respective normal and variant PCR products 
are used to test for homozygous mutations. While no 
homozygous mutations were detected by this procedure, 
both exons 6 and 4 exhibited a double-band pattern (Fig. 
1), indicating the presence of heterozygous mutations. 
Direct sequencing of the PCR-amplified exons prior to 
their cloning into pCR H confirmed the presence of two 
separate heterozygous mutations in the propositus (Fig. 2). 
3.2. Documentation of factors Xwe,,tche  I and II 
The complete nucleotide sequences of all eight exons 
and splice junctions of the factor X gene of the propositus 
A WENATCHEE I 
A C G T B , 
, 
S 
l 
3' 
WENATCHEE II 
A C G T 
5'- CTGGAA [T]GCAGG AAG -3' 
Leu~37 GIu138 _Cys139 Arg14O Lys~41 
5'-TG C CAGA[C]  CCAG GG C-3' 
Cys55 Gin56 Thr5 ? GinS8 Gly59 
Fig. 3. (A) Interpretation of autoradiograph s owing the point mutation C to T at residue 13 894 in exon 6 of the factor XWenatche  I gene. The mutation 
results in coding for Cys (TGC) instead of Arg (CGC) at amino acid position 139. (B) Interpretation of autoradiograph s owing the point mutation A to C 
at residue 9338 in exon 4 of the factor Xwenatche e II gene. The mutation results in coding for Thr (AAC) instead of Asn (ACC) at amino acid position 57. 
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Fig. 4. (A) Demonstration using 4% agarose gel electrophoresis of creation of a BsmI site in the factor Xwe,~t~h~ ~ I gene. Normal and variant 
PCR-amplified exon 6 products of 351 bp (lanes B and D, respectively) were digested with BsmI. A single BsmI site in the normal exon results in 
products of 283 and 68 bp (lane C) and a second site in the variant exon results in additional products of 186 and 97 bp (lane E), in addition to those 
produced from the normal exon. Lane A, 1 kb ladder. Sizes of PCR-amplified products and restriction fragments are shown at right. (B) Heterozygous 
occurrence of factor Xwe,atche~ I in the first of two daughters of the propositus. Shown are undigested PCR-amplified 351 bp exon 6 products of the 
second (lane B) and first (lane D) daughters of the propositus. Patterns are shown for Bsml digests of these products from the second (lane C) and first 
(lane E) daughters. Lanes A and F, 1 kb ladder. Refer to the legend of Fig. 2A regarding the sizes of the Bsml products. Sizes of PCR-amplified products 
and restriction fragments are shown at right. 
were determined and compared with those of the normal 
factor X gene [5,7], As shown by Fig. 3A, a change from a 
C to T was observed at nucleotide position 13,984 in exon 
6, resulting in a change in coding from that for Arg-139 
(CGC) to that for Cys (TGC). An exon 4 mutation (Fig. 
3B) was revealed as the substitutic.n of A by C at nu- 
A B C D E F G H I 
Fig. 5. Proof of heterozygous occurrence of factor Xwenatche e II defect in propositus and the second of two daughters. The mismatch PCR-amplified factor 
X gene 120 bp exon 4 product from a normal individual (lane B) and the corresponding product from the propositus (Lane D L second daughter (lane F) 
and first daughter (lane H) are shown. BsaJI patterns of digests of the normal product (lane C) and those of the propositus (lan,~ E), second aughter (lane 
G) and first daughter (lane I) are also shown. The patterns observed for the propositus and the second daughter are consistent with fragments of 120 bp, 96 
bp and 24 bp (latter not in the effective visualization range of the gel system used) due to the creation of a BsaJI site by the ex3n 4 mutation and with the 
heterozygous occurrence of the mutation. Sizes of PCR-amplified products and restriction fragments are shown at right. 
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22-  
14-  
"q--L 
Fig. 6. SDS-PAGE patterns of normal factor X and isolate of factors 
Xwenatche e ][ and II (combined) in the absence and presence of reducing 
agent. Non-reduced purified normal factor X (50 ng) and the variant 
isolate (100 ng) are represented in lanes A and C, respectively. The 
patterns for reduced normal factor X (90 ng) and the variant isolate (200 
ng) are shown in lanes B and D, respectively. The numbers on the left 
side of the figure indicate the sizes in kDa of components of the 
molecular weight standard used. The letters H and L indicate the migra- 
tion of heavy and light chains of factor X. 
cleotide position 9338, changing the coding at amino acid 
position 57 from that for Asn (AAC) to that for Thr 
(ACC). These changes were observed in two to four of the 
six plasmid DNA preparations generated from each of two 
separate PCR amplifications of the respective variant ex- 
ORS. 
The exon 6 mutation creates a BsmI restriction site, as 
illustrated by the results shown in Fig. 4A, indicating 
heterozygosity of this occurrence in the patient's genomic 
DNA. That the exon 6 mutation occurs in only one of two 
daughters is shown by Fig. 4B. The exon 4 mutation 
creates a BsaJI recognition site, juxtaposed to a normally 
occurring BsaJI site. Therefore, in order to be able to use 
the creation of a new site for confirmation of the heterozy- 
gous occurrence of the detected mutation, an antisense 
primer was designed to remove the normally existing 
BsaJI site in the process of employing the altered primer 
for mismatch amplification of a 5' fragment of exon 4 (see 
Section 2). The findings, confirming the heterozygous 
occurrence of the form II mutation in the propositus and in 
the second of two daughters, are shown in Fig. 5. Normal 
BsmI and BsaJI restriction patterns were observed in 
amplified exon 6 and exon 4 fragments of DNA from 25 
unrelated normal Caucasian blood donors, representing 50 
factor X genes. 
3.3. Analysis of heavy and light chains of factors Xw~...:he ~ 
I and H (combined) 
Bands corresponding to normal intact factor X and to 
the heavy and light chains produced by reducing agent 
A B C D E F 
kDa 
69- 
46-  
30-  
"q--X 
22- 
14-  
Fig. 7. Western blotting patterns for factor X derived from plasma of propositus and two daughters. Samples without reducing agent from the propositus 
(A, 100 ng), the first daughter (C, 40 ng) and the second aughter (E, 40 ng) were compared with reduced samples for the propositus (B, 100 ng), first 
daughter (D, 40 ng) and second aughter (F, 40 ng). The letters to the right indicate the mobilities of intact normal factor X (X), and the normal heavy (H) 
and light (L) chains. 
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were obtained in SDS-PAGE for the combined variant 
factor preparation (Fig. 6). However, the reduced variant 
preparation also exhibited an additional band essentially 
corresponding in size to that of the unreduced molecule 
(see lane D of Fig. 6). This additional band was taken to 
represent a single-chain species, although it has a slightly 
higher mobility than that of intact normal factor X (lane A 
of Fig. 6). By the Western blotting procedure, the apparent 
single-chain species of factor X was detected for both the 
propositus and the daughter who inherited Wenatchee form 
I (Fig. 7). The daughter with Wenatchee form II exhibited 
bands corresponding in mobility to normal factor X and 
the normal heavy chain. The rabbit polyclonal antibody 
used in this procedure reacted preferentially with the heavy 
chain of factor X, and thus was useful in detection of 
intact factor X or the free heavy chain, as seen in Fig. 7. 
3.4. Acticio, o f  purified factors X w ....... .h~ I and H (com- 
bined) 
The purified preparation of factors Xwenatche e I and II 
(combined) was tested in the systems for activation by the 
RVV-X, intrinsic and extrinsic pathways. The values ob- 
tained in these assays, referred to the values for normal 
factor X, were 28%, 33% and 45%, respectively. The 
latter data correspond to 8.4%, 10.0% and 13.5% of nor- 
mal plasma levels, when recalculated to reflect theoretical 
activity on the basis of circulating antigen levels of 30% of 
normal. The differences between these calculated values, 
which are higher than the observed values (Table 1) in the 
assays for plasma of the propositus, could be related to the 
effect of inhibitors to factor X in the variant plasma. 
4. Discussion 
Of the few missense mutations described in factor X 
deficient patients, none have previously been reported in 
either exon 4 or 6. Precedents for these mutations were 
then examined in the more frequently studied factor IX 
genes of hemophilia B patients. In factor X the last residue 
of the carboxyl terminus of the light chain is Arg-139, 
equivalent to Arg-145 in factor IX. In factor X, however, a
basic tripeptide (Arg-140-Lys-141-Arg-142) is cleaved on 
either end from the circulating factor X zymogen. It thus 
appears that the processing protease requires Arg at the 
-4  position and/or that the presence of a new, unpaired 
SH group (Cys-139) prevents processing protease recogni- 
tion and/or cleavage. In hemophilia B, Arg-145 to Cys is 
associated with moderately severe activity deficiency and a 
mildly reduced antigen level [19]. 
Within the first epidermal growth factor (EGF)-Iike 
domain, Asn-57 is the equivalent of Ash-58 in factor IX 
and is conserved in all species of factors VII, IX and X 
sequenced. However, other residues are present at this 
position in proteins C and S. In factor IX, Gly-60 to Ser is 
a common, recurrent mutation that produces mild 
hemophilia B with somewhat reduced total antigen levels 
[19]. There have been no mutations reported of Asn-58 in 
the factor IX gene of hemophilia B patients, but Gly-59 is 
Thr in the native canine protein [20]. 
That neither of the patient's factor X mutations was 
found in screening 50 factor X genes from normal Cau- 
casian donors excludes their presence being due to simple 
polymorphisms. A rare variant hat may not affect activity, 
however, cannot be excluded. Witl:: the absence of any 
other mutations within the coding regions of his two factor 
X genes, however, it is likely that the patient's mild 
bleeding tendency results from compound heterozygosity 
due to both the Cys-139 and Thr-57 variants identified in 
the present study. The latter statement is strongly sup- 
ported by the fact that both the normal and variant factors 
X used for analysis of activity profiles were purified by the 
same procedure. 
Based upon SDS-PAGE patterns of purified factor 
Xwenatche e I and II (combined) in the presence and absence 
of reducing agent, a single-chain molecular species was 
detected that could represent form 1. Further support for 
this idea was provided by the Western blotting results 
depicted in Fig. 7, which show the putative single-chain 
species for the propositus and for daughter A in the 
reduced factor X samples (lanes B and D, Fig. 7). The 
heavy chain band in the sample from daughter A is 
assumed to derive from normal factc,r X, while the corre- 
sponding band in the sample from the propositus is as- 
sumed to derive from Wenatchee ferm II. The relatively 
higher concentration of the single-chain species to heavy 
chain in the reduced Western blotting sample for the 
propositus (lane B, Fig. 7) is consistent with the relative 
intensities of these components observed by SDS-PAGE 
(lane D, Fig. 6). Daughter B exhibited only the expected 
intact factor X band under non-reducing conditions (lane 
E, Fig. 7) and only the heavy chain of factor X under 
reducing conditions (lane F, Fig. 7). The higher molecular 
weight bands visible in Fig. 7 could possibly represent a
dimer of factor Xweoatche e I. formed through the new 
unpaired cysteine created by the mutations. If so, it could 
be further postulated, with reference to Fig. 6 (lane D), that 
this high molecular weight species does not completely 
disappear from the reduced sample due to an increased 
resistance to reduction. Another less likely possibility is 
that the higher molecular weight species represents a cova- 
lent combination of form I with one ef the plasma protease 
inhibitors. Specifically related to the cysteine at position 
139, our attempts (not shown) to selectively bind form I to 
Thiopropyl-Sepharose were unsuccessful, indicating the 
presence of a new disulfide bond (as in dimer formation), 
or spacial unavailability of a new sul fhydryl group. 
Factor X is synthesized in vivo as a single chain with a 
M r of approx. 59000 and is converled to the circulating 
two-chain, single disulfide connected form upon process- 
ing removal of a tripeptide, Arg- 140- Lys- 141 -Arg- 142 [5]. 
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Thus, Arg-139 becomes the C-terminal residue of the light 
chain (M r = 16000), while the peptide Leu-143-Arg-194, 
constitutes the peptide cleaved from the N-terminal end of 
the heavy chain (M r = 43000) when factor X is proteo- 
lytically activated to factor Xa [21]. Thus, form I likely 
represents a single-chain species containing both the light 
and heavy chains joined not only by the normal disulfide 
bond, but also by the interposed Arg- 140-Lys- 141-Arg- 142 
tripeptide. Reduction of the intra-chain disulfide bonds - 
of which there are 11 in factor X [5] - in proteins is 
known to reduce their mobility in SDS-PAGE. However, it 
is possible that the presence of Cys at position 139 could 
cause structural changes that affect the overall shape, and 
thus electrophoretic mobility, of the molecule. Due to the 
marginal evels of factor X activities in the assays mea- 
sured vs antigenic levels of the combined variants from the 
propositus and the significantly reduced factor X activity 
levels in daughter B (Table 1), form II could also be 
functionally defective due to a disrupture ffect of the 
mutation on the interactive properties of the light chain. 
Due to the lack of an effective method for the separa- 
tion of factors Xwenatche c I and I1, current effort toward 
detailed characterization f the variant proteins is focused 
on their expression in an eukaryotic system. Such an 
approach, combined with use of the immunoaffinity purifi- 
cation procedures described in the present study, is ex- 
pected to yield sufficient quantities of both variants in their 
native forms for biochemical characterization, e.g., pres- 
ence of carbohydrate, g ~ ",/-carboxylated glutamic acid 
side chains and a suspected free sulfhydryl group (in form 
I). Moreover, we will be able to more accurately determine 
their respective capacities for activation, binding to other 
physiologically relevant coagulation factors, and catalytic 
functions. 
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